Drugs / Rouvax
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT01231503 Background | Jan 2011 → Apr 2014 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00891007 Comparator | Jun 2009 → Jul 2010 | measles | Bavarian Nordic | Completed | No outcome recorded |
| Phase 2 | NCT00436007 Background | Apr 2007 → Sep 2008 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| — | NCT00820820 Comparator | Jan 2009 → Mar 2012 | atopic eczema | French National Institute of Health and Medical Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rouvax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00891007 ↗ |
| Modality | Vaccine | “Aventis Pasteur's attenuated measles vaccine.” NCT00436007 ↗ |
| Route | Intramuscular | “Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively.” NCT00436007 ↗ |